7,091,051 Shares in Certara, Inc. $CERT Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in shares of Certara, Inc. (NASDAQ:CERT) during the 2nd quarter, Holdings Channel reports. The firm bought 7,091,051 shares of the company’s stock, valued at approximately $46,446,000.

A number of other hedge funds also recently added to or reduced their stakes in CERT. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares during the period. Osaic Holdings Inc. boosted its position in Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares during the last quarter. State of Wyoming purchased a new position in shares of Certara in the second quarter valued at $72,000. Finally, Pacer Advisors Inc. raised its stake in shares of Certara by 28.1% during the 1st quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after buying an additional 2,871 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Performance

Shares of CERT opened at $8.41 on Friday. Certara, Inc. has a 1 year low of $4.45 and a 1 year high of $13.88. The company’s 50 day simple moving average is $7.31 and its 200 day simple moving average is $6.46. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -18.69 and a beta of 1.44. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business had revenue of $93.27 million during the quarter, compared to analyst estimates of $98.09 million. During the same quarter last year, the firm posted $0.07 earnings per share. The company’s revenue was down 10.8% on a year-over-year basis. On average, sell-side analysts predict that Certara, Inc. will post 0.22 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Stephens cut their target price on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Robert W. Baird cut their price objective on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, May 12th. Craig Hallum reduced their target price on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings raised Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, August 5th. Finally, Morgan Stanley reduced their price objective on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.28.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.